Related Articles
The efficacy of immune checkpoint inhibitors in advanced non‑small cell lung cancer harboring driver mutations
Predictive value of tumor genetic alteration profiling for chemotherapy and EGFR‑TKI treatment in advanced NSCLC
Overall survival in stage IV EGFR mutation‑positive NSCLC: Comparing first‑, second‑ and third‑generation EGFR‑TKIs (Review)
Survival of patients with pancreatic cancer treated with varied modalities: A single-centre study
Plasma neuron-specific enolase level as a prognostic marker in patients with non-small cell lung cancer receiving gefitinib